Competition & Peer Data API & CSV Delivery Connect to AI Assistant via MCP

Ortho Clinical Diagnostics Holdings Plc's Competitiveness

A competitive positioning analysis and financial ratio benchmarking of Ortho Clinical Diagnostics Holdings Plc (OCDX) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.

Peer Data As of Q1 2022
Competitors
1
Named by the company
Peer Group Market Share
100.00 %
vs 100.00 % a year ago
Revenue Growth Y/Y
-1.32 %
Q1 2022
Net Margin
2.96 %
Q1 2022

Key Findings: Ortho Clinical Diagnostics Holdings Plc vs Its Competitors

  • TTM: Trailing 12-month revenue of 2,036M vs -M combined for its competitors (100.0% combined share).
  • Trending: Latest-quarter revenue run-rate is holding steady (-1.8% annualized vs trailing 12 months).
  • Peer revenue share: Ortho Clinical Diagnostics Holdings Plc accounted for 100.0% of combined revenue among its tracked peer group, up from 100.0% a year earlier.
  • Structure: Ortho Clinical Diagnostics Holdings Plc operates in the following segments: Reportable.

Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).

OCDX Sales vs. its Competitors, Q1 2022

Ortho Clinical Diagnostics Holdings Plc generated 100.00 % of the combined sales of its peer group, up from 100.00 % a year earlier.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/OCDX/competitors
https://api.csimarket.com/api/v1/companies/OCDX/relationships
https://api.csimarket.com/api/v1/companies/OCDX/similar
Programmatic access for models, analytics, and integration workflows.
Explore the Financial Data API

For context: the In Vitro & In Vivo Diagnostic Substances industry grew revenue 3.0% year over year, combined, vs -1.3% for Ortho Clinical Diagnostics Holdings Plc. Ortho Clinical Diagnostics Holdings Plc's share of combined industry revenue moved from 15.25% to 14.61%, a loss of 0.64 percentage points.

Ortho Clinical Diagnostics Holdings Plc's Competitor Quality Breadth

Group definitions: see Methodology: Performance Group Definitions.

Entity Profitable Expanding Above Industry Growth Distressed
Ortho Clinical Diagnostics Holdings Plc No Yes Yes Yes
High-Confidence Competitors (1) 0% 100% 100% 100%
Similar Growth & Profitability (8) 25.00 % (2 of 8) 37.50 % (3 of 8) 62.50 % (5 of 8) 12.50 % (1 of 8)

Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.

Market Share of the Peer Group, Q1 2022

100%market share
  • Ortho Clinical Diagnostics Holdings Plc100.0%
  • Competitors combined0.0%

Share of combined quarterly revenue of Ortho Clinical Diagnostics Holdings Plc and its 1 competitors.

See Ortho Clinical Diagnostics Holdings Plc's full market share breakdown »

OCDX Stock Performance relative to its Competitors

OCDX Competitors (weighted) Percent change over the selected range

Ortho Clinical Diagnostics Holdings Plc's Share Price Performance vs Peer Groups

Trailing 12-month total share price return, and the share of each group that outperformed the U.S.A. 500 over the same period. Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC.
0%beat U.S.A. 500
High-Confidence
(0 of 1)
50%beat U.S.A. 500
Similar Growth & Profitability
(3 of 6)
Entity TTM Share Price Return
(group: median)
vs U.S.A. 500
Ortho Clinical Diagnostics Holdings Plc - -
Competitors combined (0) 40.4% 63.2%
High-Confidence Competitors (1) 40.4% 63.2%
Similar-Size Competitors (0) 40.4% 63.2%
Similar Growth & Profitability (6) 40.4% 63.2%
Peer Group Share Price Returns

TTM share price return and U.S.A. 500 outperformance for Ortho Clinical Diagnostics Holdings Plc's competitor groups requires a Commercial License.

Source: CSIMarket API (daily market-structure computation). Outperformance is trailing-12-month total return vs the U.S.A. 500 over the same window, not risk-adjusted.

OCDX Stock Performance relative to High-Confidence Competitors

OCDX High-Confidence Competitors (equal-weighted, 1) Percent change over the selected range

OCDX Stock Performance relative to Similar Growth & Profitability Competitors

OCDX Similar Growth & Profitability Competitors (equal-weighted, 8) Percent change over the selected range

Ortho Clinical Diagnostics Holdings Plc's Competitors Named by the Company

Competitive relationships identified from Ortho Clinical Diagnostics Holdings Plc reports and corroborating sources, each with a basis and confidence.
Competitor Basis Confidence Active Sources
Quanterix Corporation Company report 85% 2022 to 2026 3
Competitor Evidence Detail

Company report basis, confidence, active dates and source counts for Ortho Clinical Diagnostics Holdings Plc's named competitors require a Commercial License.

Methodology: see Methodology: Peer & Competitor Identification, Sourcing.

Ortho Clinical Diagnostics Holdings Plc's Business Segment Mix vs Peers

Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).
Company Largest Segment 2nd Segment 3rd Segment
Ortho Clinical Diagnostics Holdings Plc Reportable 87.72 % - -

Source: operating segment revenue as reported in each company's reports (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).

Get the full CSIMarket dataset: Subscribe API Connect Your AI